Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 150

1.

Stability of the nicotine metabolite ratio in smokers of progressively reduced nicotine content cigarettes.

St Helen G, Jacob P 3rd, Benowitz NL.

Nicotine Tob Res. 2013 Nov;15(11):1939-42. doi: 10.1093/ntr/ntt065. Epub 2013 May 14.

2.

Nicotine Metabolism in Young Adult Daily Menthol and Nonmenthol Smokers.

Fagan P, Pokhrel P, Herzog TA, Pagano IS, Franke AA, Clanton MS, Alexander LA, Trinidad DR, Sakuma KL, Johnson CA, Moolchan ET.

Nicotine Tob Res. 2016 Apr;18(4):437-46. doi: 10.1093/ntr/ntv109. Epub 2015 May 19.

3.

Effect of reducing the nicotine content of cigarettes on cigarette smoking behavior and tobacco smoke toxicant exposure: 2-year follow up.

Benowitz NL, Nardone N, Dains KM, Hall SM, Stewart S, Dempsey D, Jacob P 3rd.

Addiction. 2015 Oct;110(10):1667-75. doi: 10.1111/add.12978. Epub 2015 Jul 21.

4.

Nicotine Dependence, Nicotine Metabolism, and the Extent of Compensation in Response to Reduced Nicotine Content Cigarettes.

Bandiera FC, Ross KC, Taghavi S, Delucchi K, Tyndale RF, Benowitz NL.

Nicotine Tob Res. 2015 Sep;17(9):1167-72. doi: 10.1093/ntr/ntu337. Epub 2015 Jan 2.

5.

CYP2A6 genotype, phenotype, and the use of nicotine metabolites as biomarkers during ad libitum smoking.

Malaiyandi V, Goodz SD, Sellers EM, Tyndale RF.

Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1812-9.

6.

Reproducibility of the nicotine metabolite ratio in cigarette smokers.

St Helen G, Novalen M, Heitjan DF, Dempsey D, Jacob P 3rd, Aziziyeh A, Wing VC, George TP, Tyndale RF, Benowitz NL.

Cancer Epidemiol Biomarkers Prev. 2012 Jul;21(7):1105-14. doi: 10.1158/1055-9965.EPI-12-0236. Epub 2012 May 2.

7.

Stability of the nicotine metabolite ratio in ad libitum and reducing smokers.

Mooney ME, Li ZZ, Murphy SE, Pentel PR, Le C, Hatsukami DK.

Cancer Epidemiol Biomarkers Prev. 2008 Jun;17(6):1396-400. doi: 10.1158/1055-9965.EPI-08-0242.

8.

Biomonitoring of urinary cotinine concentrations associated with plasma levels of nicotine metabolites after daily cigarette smoking in a male Japanese population.

Nagano T, Shimizu M, Kiyotani K, Kamataki T, Takano R, Murayama N, Shono F, Yamazaki H.

Int J Environ Res Public Health. 2010 Jul;7(7):2953-64. doi: 10.3390/ijerph7072953. Epub 2010 Jul 20.

9.

Nicotine metabolite ratio as a predictor of cigarette consumption.

Benowitz NL, Pomerleau OF, Pomerleau CS, Jacob P 3rd.

Nicotine Tob Res. 2003 Oct;5(5):621-4.

PMID:
14577978
10.

Nicotine metabolite ratio (3-hydroxycotinine/cotinine) in plasma and urine by different analytical methods and laboratories: implications for clinical implementation.

Tanner JA, Novalen M, Jatlow P, Huestis MA, Murphy SE, Kaprio J, Kankaanpää A, Galanti L, Stefan C, George TP, Benowitz NL, Lerman C, Tyndale RF.

Cancer Epidemiol Biomarkers Prev. 2015 Aug;24(8):1239-46. doi: 10.1158/1055-9965.EPI-14-1381. Epub 2015 May 26.

11.

Variation in trans-3'-hydroxycotinine glucuronidation does not alter the nicotine metabolite ratio or nicotine intake.

Zhu AZ, Zhou Q, Cox LS, Ahluwalia JS, Benowitz NL, Tyndale RF.

PLoS One. 2013 Aug 2;8(8):e70938. doi: 10.1371/journal.pone.0070938. Print 2013.

12.

Known and novel sources of variability in the nicotine metabolite ratio in a large sample of treatment-seeking smokers.

Chenoweth MJ, Novalen M, Hawk LW Jr, Schnoll RA, George TP, Cinciripini PM, Lerman C, Tyndale RF.

Cancer Epidemiol Biomarkers Prev. 2014 Sep;23(9):1773-82. doi: 10.1158/1055-9965.EPI-14-0427. Epub 2014 Jul 10.

13.

Determination of the nicotine metabolites cotinine and trans-3'-hydroxycotinine in biologic fluids of smokers and non-smokers using liquid chromatography-tandem mass spectrometry: biomarkers for tobacco smoke exposure and for phenotyping cytochrome P450 2A6 activity.

Jacob P 3rd, Yu L, Duan M, Ramos L, Yturralde O, Benowitz NL.

J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Feb 1;879(3-4):267-76. doi: 10.1016/j.jchromb.2010.12.012. Epub 2010 Dec 21.

14.

The Nicotine Metabolite Ratio in Pregnancy Measured by trans-3'-Hydroxycotinine to Cotinine Ratio: Characteristics and Relationship With Smoking Cessation.

Vaz LR, Coleman T, Cooper S, Aveyard P, Leonardi-Bee J; SNAP trial team.

Nicotine Tob Res. 2015 Nov;17(11):1318-23. doi: 10.1093/ntr/ntu342. Epub 2015 Jan 14.

PMID:
25589677
15.

Test-Retest Reliability and Stability of the Nicotine Metabolite Ratio Among Treatment-Seeking Smokers.

Hamilton DA, Mahoney MC, Novalen M, Chenoweth MJ, Heitjan DF, Lerman C, Tyndale RF, Hawk LW Jr.

Nicotine Tob Res. 2015 Dec;17(12):1505-9. doi: 10.1093/ntr/ntv031. Epub 2015 Mar 1.

16.

Smoking behavior and exposure to tobacco toxicants during 6 months of smoking progressively reduced nicotine content cigarettes.

Benowitz NL, Dains KM, Hall SM, Stewart S, Wilson M, Dempsey D, Jacob P 3rd.

Cancer Epidemiol Biomarkers Prev. 2012 May;21(5):761-9. doi: 10.1158/1055-9965.EPI-11-0644. Epub 2012 Feb 21.

17.

Nicotine metabolite ratio predicts smoking topography and carcinogen biomarker level.

Strasser AA, Benowitz NL, Pinto AG, Tang KZ, Hecht SS, Carmella SG, Tyndale RF, Lerman CE.

Cancer Epidemiol Biomarkers Prev. 2011 Feb;20(2):234-8. doi: 10.1158/1055-9965.EPI-10-0674. Epub 2011 Jan 6.

18.

Nicotine metabolite ratio predicts efficacy of transdermal nicotine for smoking cessation.

Lerman C, Tyndale R, Patterson F, Wileyto EP, Shields PG, Pinto A, Benowitz N.

Clin Pharmacol Ther. 2006 Jun;79(6):600-8. Epub 2006 May 11.

PMID:
16765148
19.
20.

Disposition kinetics and metabolism of nicotine and cotinine in African American smokers: impact of CYP2A6 genetic variation and enzymatic activity.

Benowitz NL, St Helen G, Dempsey DA, Jacob P 3rd, Tyndale RF.

Pharmacogenet Genomics. 2016 Jul;26(7):340-50. doi: 10.1097/FPC.0000000000000222.

Supplemental Content

Support Center